Production (Stage)
Apellis Pharmaceuticals, Inc.
APLS
$17.44
-$0.34-1.91%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -3.21% | 45.19% | 78.29% | 110.26% | 284.26% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -3.21% | 45.19% | 78.29% | 110.26% | 284.26% |
| Cost of Revenue | 15.13% | 31.41% | 19.93% | -2.87% | -10.97% |
| Gross Profit | -31.74% | 66.69% | 771.90% | 1,187.76% | 192.36% |
| SG&A Expenses | -0.12% | -14.27% | -16.25% | 15.00% | 26.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.70% | 3.38% | -1.36% | 6.37% | 6.59% |
| Operating Income | -34.21% | 69.04% | 65.51% | 75.55% | 64.54% |
| Income Before Tax | -38.69% | 58.62% | 59.39% | 69.19% | 62.67% |
| Income Tax Expenses | 100.59% | -79.90% | 154.08% | -41.24% | -39.72% |
| Earnings from Continuing Operations | -38.84% | 58.96% | 59.04% | 69.14% | 62.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -38.84% | 58.96% | 59.04% | 69.14% | 62.64% |
| EBIT | -34.21% | 69.04% | 65.51% | 75.55% | 64.54% |
| EBITDA | -34.45% | 69.40% | 65.73% | 75.84% | 64.71% |
| EPS Basic | -36.08% | 60.05% | 60.34% | 70.29% | 65.40% |
| Normalized Basic EPS | -35.93% | 59.72% | 60.68% | 71.87% | 65.43% |
| EPS Diluted | -36.08% | 60.05% | 60.34% | 70.29% | 65.40% |
| Normalized Diluted EPS | -35.93% | 59.72% | 60.68% | 71.87% | 65.43% |
| Average Basic Shares Outstanding | 2.03% | 2.71% | 3.28% | 3.85% | 7.98% |
| Average Diluted Shares Outstanding | 2.03% | 2.71% | 3.28% | 3.85% | 7.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |